Immune reconstitution and severity of COVID-19 among hematopoietic cell transplant recipients

Alexandre E. Malek; Javier A. Adachi; Victor E. Mulanovich; Joseph Sassine; Issam I. Raad; Kelly McConn; Garret T. Seiler; Udit Dhal; Fareed Khawaja; Roy F. Chemaly

doi:10.1111/tid.13606

Immune reconstitution and severity of COVID-19 among hematopoietic cell transplant recipients

Alexandre E. Malek, Javier A. Adachi, Victor E. Mulanovich, Joseph Sassine, Issam I. Raad, Kelly McConn, Garret T. Seiler, Udit Dhal, Fareed Khawaja, Roy F. Chemaly

Infectious Diseases, Infection Control, and Employee Health

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Severe acute respiratory syndrome coronavirus 2 can lead to life-threatening coronavirus disease 2019 (COVID-19) infections in patients with hematologic malignancies, particularly among hematopoietic cell transplant (HCT) recipients. We describe two patients with COVID-19 during the pre-engraftment period after HCT and review previous reports of COVID-19 in HCT recipients. Because of significant mortality from COVID-19, primarily after allogeneic HCT, early, preemptive, and optimal directed therapy may improve outcomes and reduce the mortality rate but still needs to be established in clinical trials.

Original language	English (US)
Article number	e13606
Journal	Transplant Infectious Disease
Volume	23
Issue number	4
DOIs	https://doi.org/10.1111/tid.13606
State	Published - Aug 2021

Keywords

COVID-19
hematopoietic cell transplantation
outcomes
pre-engraftment
stem cell therapy

ASJC Scopus subject areas

Infectious Diseases
Transplantation

Access to Document

10.1111/tid.13606

Cite this

@article{fefee27ad1144421898d72545fba27b4,

title = "Immune reconstitution and severity of COVID-19 among hematopoietic cell transplant recipients",

abstract = "Severe acute respiratory syndrome coronavirus 2 can lead to life-threatening coronavirus disease 2019 (COVID-19) infections in patients with hematologic malignancies, particularly among hematopoietic cell transplant (HCT) recipients. We describe two patients with COVID-19 during the pre-engraftment period after HCT and review previous reports of COVID-19 in HCT recipients. Because of significant mortality from COVID-19, primarily after allogeneic HCT, early, preemptive, and optimal directed therapy may improve outcomes and reduce the mortality rate but still needs to be established in clinical trials.",

keywords = "COVID-19, hematopoietic cell transplantation, outcomes, pre-engraftment, stem cell therapy",

author = "Malek, {Alexandre E.} and Adachi, {Javier A.} and Mulanovich, {Victor E.} and Joseph Sassine and Raad, {Issam I.} and Kelly McConn and Seiler, {Garret T.} and Udit Dhal and Fareed Khawaja and Chemaly, {Roy F.}",

note = "Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC.",

year = "2021",

month = aug,

doi = "10.1111/tid.13606",

language = "English (US)",

volume = "23",

journal = "Transplant Infectious Disease",

issn = "1398-2273",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Immune reconstitution and severity of COVID-19 among hematopoietic cell transplant recipients

AU - Malek, Alexandre E.

AU - Adachi, Javier A.

AU - Mulanovich, Victor E.

AU - Sassine, Joseph

AU - Raad, Issam I.

AU - McConn, Kelly

AU - Seiler, Garret T.

AU - Dhal, Udit

AU - Khawaja, Fareed

AU - Chemaly, Roy F.

PY - 2021/8

Y1 - 2021/8

N2 - Severe acute respiratory syndrome coronavirus 2 can lead to life-threatening coronavirus disease 2019 (COVID-19) infections in patients with hematologic malignancies, particularly among hematopoietic cell transplant (HCT) recipients. We describe two patients with COVID-19 during the pre-engraftment period after HCT and review previous reports of COVID-19 in HCT recipients. Because of significant mortality from COVID-19, primarily after allogeneic HCT, early, preemptive, and optimal directed therapy may improve outcomes and reduce the mortality rate but still needs to be established in clinical trials.

AB - Severe acute respiratory syndrome coronavirus 2 can lead to life-threatening coronavirus disease 2019 (COVID-19) infections in patients with hematologic malignancies, particularly among hematopoietic cell transplant (HCT) recipients. We describe two patients with COVID-19 during the pre-engraftment period after HCT and review previous reports of COVID-19 in HCT recipients. Because of significant mortality from COVID-19, primarily after allogeneic HCT, early, preemptive, and optimal directed therapy may improve outcomes and reduce the mortality rate but still needs to be established in clinical trials.

KW - COVID-19

KW - hematopoietic cell transplantation

KW - outcomes

KW - pre-engraftment

KW - stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=85103910787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103910787&partnerID=8YFLogxK

U2 - 10.1111/tid.13606

DO - 10.1111/tid.13606

M3 - Article

C2 - 33755273

AN - SCOPUS:85103910787

SN - 1398-2273

VL - 23

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

IS - 4

M1 - e13606

ER -

Immune reconstitution and severity of COVID-19 among hematopoietic cell transplant recipients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this